584 related articles for article (PubMed ID: 26921100)
41. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.
Silverman LB
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):259-264. PubMed ID: 29222264
[TBL] [Abstract][Full Text] [Related]
42. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
Dahl J; Mace M; Kantarjian H; Jabbour E
Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
[TBL] [Abstract][Full Text] [Related]
43. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
[TBL] [Abstract][Full Text] [Related]
44. New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.
Advani AS
Hematology Am Soc Hematol Educ Program; 2013; 2013():131-7. PubMed ID: 24319174
[TBL] [Abstract][Full Text] [Related]
45. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
[TBL] [Abstract][Full Text] [Related]
46. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
47. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
Mahalleh M; Shabani M; Rayzan E; Rezaei N
Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
[TBL] [Abstract][Full Text] [Related]
48. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
49. Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
Kimble EL; Cassaday RD
Leuk Lymphoma; 2021 Dec; 62(14):3333-3347. PubMed ID: 34402732
[TBL] [Abstract][Full Text] [Related]
50. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
51. [Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review].
Su Y; Yin QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):648-652. PubMed ID: 33812446
[TBL] [Abstract][Full Text] [Related]
52. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies.
O'Dwyer KM; Liesveld JL
Best Pract Res Clin Haematol; 2017 Sep; 30(3):184-192. PubMed ID: 29050691
[TBL] [Abstract][Full Text] [Related]
53. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
54. [CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].
Fu XH; Wang Y; Wang HJ; Wei SN; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):282-286. PubMed ID: 32447930
[No Abstract] [Full Text] [Related]
55. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
Lussana F; Gritti G; Rambaldi A
J Clin Oncol; 2021 Feb; 39(5):444-455. PubMed ID: 33434063
[No Abstract] [Full Text] [Related]
56. Advances in T-cell therapy for ALL.
Grupp SA
Best Pract Res Clin Haematol; 2014; 27(3-4):222-8. PubMed ID: 25455270
[TBL] [Abstract][Full Text] [Related]
57. Adult Acute Lymphoblastic Leukemia.
Paul S; Kantarjian H; Jabbour EJ
Mayo Clin Proc; 2016 Nov; 91(11):1645-1666. PubMed ID: 27814839
[TBL] [Abstract][Full Text] [Related]
58. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
59. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy in adult acute leukemia.
Blum S; Martins F; Lübbert M
Leuk Res; 2017 Sep; 60():63-73. PubMed ID: 28756350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
